Caring for a family member with a brain condition that has no known effective treatment and a challenging prognosis is extremely difficult. The family and medical dynamics involved can be overwhelming.
A year ago, the Plus One Foundation introduced our branded education program, Think aBout It. Last month, we expanded the initiative to include biomarkers, launching an educational piece focused on brain injury signature markers. We also know that individuals with brain injuries have an increased risk of developing future cognitive conditions. In this article, we discuss the first Food and Drug Administration–approved blood test for diagnosing Alzheimer’s, the most common type of dementia in the United States. This breakthrough could transform how we detect and manage cognitive decline, offering new hope for patients and families alike.
